Effect of levosimendan on plasma intestinal barrier factors in heart failure patients with reduced ejection fraction.
Levosimendan not only improves HF and gastrointestinal symptoms in hospitalized patients with acute exacerbation of HFrEF but also reduces plasma intestinal barrier factor levels. These effects may be associated with decreased plasma proinflammatory cytokines and increased anti-inflammatory cytokines after treatment, potentially involving IL-17 and TNF signaling pathways.
Institutions
- Central South University (CN)
- National Clinical Research (US)
- Third Xiangya Hospital (CN)
- Xiangya Hospital Central South University (CN)
Publication Details
- Journal
- PubMed
- Published
- 2026-01-06
- DOI
- https://doi.org/10.11817/j.issn.1672-7347.2025.250423
- Primary Topic
- Heart Failure Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 0.00